In contrast, the levels of CD8+ and CD4+ cells in the BM and spleen were higher in AML mice treated with Tri-T cell infusion than in the AML mice that were not treated with Tri-T cell infusion (for CD8+ cells in the BM, 26.69% ± 2.10% versus 7.71% ± 4.18%; in the spleen, 38.65% ± 16.47% versus 3.06% ± 1.75%; for CD4+ cells in the BM, 12.83% ± 4.54% versus 5.73% ± 1.81%; in the spleen, 26.85% ± 10.01% versus 1.83% ± 0.45%; Figure 5C), indicating the cytotoxic activity of Tri-T cells against leukemic cells in vivo. The gene discussed is CD8A; the disease is acute myeloid leukemia.